CJC-1295 (No DAC) / IpamorelinExplore study findings
What a study would need to attribute a response to either peptide
3 numbered sourcesSource years 1995, 2024
Peptide bonds join amino acids into short chains that can send signals. When two signaling peptides appear under a single label, researchers need to distinguish what each contributes. CJC-1295 (No DAC) / Ipamorelin lists a modified 29-residue growth hormone–releasing hormone analogue and a five-residue agonist of the ghrelin receptor. Would comparing the two together against a control be enough to tell how they interact? [1, 2]
No recent primary study of the exact pair was identified. A 1995 human challenge provides an older comparison with different compounds. It measured growth hormone after unmodified GHRH(1–29), after GHRP-2, and after the two were given together. Because each participant experienced the three conditions, the investigators could compare the combined result with the responses to the two compounds separately. The combined result was larger than the GHRP-2 result, but the study did not demonstrate an effect beyond what the individual results would predict under its comparison rule. [3]
For the catalog pairing, a comparison between the blend and a control could show whether the blend changed an outcome. Without a separate comparison for each ingredient, it would leave open whether the change came from one constituent, both or an interaction between them. A design measuring changes at several times could also ask whether an interaction appeared early, late or only at a particular part of the hormone curve. [3]
The precedent used GHRP-2 in place of ipamorelin and a different GHRH sequence. It illustrates why comparison groups matter. Any finding about interaction between Mod GRF (1–29) and ipamorelin would require direct testing of those two molecules. [1, 2, 3]
Sources
Original works cited in this article. Links open the external record in a new tab.
